{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:27:18Z","timestamp":1747178838075,"version":"3.40.5"},"reference-count":46,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Genor Biopharma Co. Ltd"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1080\/14712598.2021.1954157","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T11:37:58Z","timestamp":1625744278000},"page":"253-262","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial"],"prefix":"10.1080","volume":"22","author":[{"given":"Wenliang","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suping","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Science and Research, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianzhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing United-Power Pharma Tech Co.,Ltd, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"School of Pharmacy, Xuzhou Medical University, Xuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9789-034X","authenticated-orcid":false,"given":"Jiaxue","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical, Peking University, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"},{"name":"School of Pharmacy, Xuzhou Medical University, Xuzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Units, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaying","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Science and Research, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenwei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Science and Research, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Clinical and Registration, Genor Biopharm Co., Ltd., Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youzhong","family":"an","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[{"name":"The Center for Drug Clinical Research of Shanghai University of TCM, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiying","family":"Rao","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeOmics, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3547-5829","authenticated-orcid":false,"given":"Yi","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.013"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01088-0"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.01.021"},{"key":"e_1_3_8_7_1","unstructured":"FDA. AVASTIN\u00ae(bevacizumab) injection for intravenous use Initial U.S. Approval 2004. [cited 2020]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/125085lbl.pdf."},{"key":"e_1_3_8_8_1","unstructured":"EMA. Human medicine European public assessment report(EPAR): avastin 2005. [cited 2020]. Avaliable from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin."},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181da36f4"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5466"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph10010019"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw213"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13552"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.004"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.025734"},{"key":"e_1_3_8_17_1","unstructured":"EMA. Similar biological medicinal products (overarching guideline). CHMP\/437\/04 Rev. 1. [cited 2020] Avaliable from: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf."},{"key":"e_1_3_8_18_1","unstructured":"FDA. BIOSIMILARS ACTION PLAN: balancing Innovation and Competition. 2018Jul [cited 2020] Avaliable from: https:\/\/www.fda.gov\/media\/114574\/download."},{"key":"e_1_3_8_19_1","unstructured":"NMPA. Guidelines for the development and evaluation of similar biological products. 2015. [cicted 2020] Avaliable from: https:\/\/www.nmpa.gov.cn\/yaopin\/ypjgdt\/20150303155101860.html."},{"key":"e_1_3_8_20_1","unstructured":"EMA. Guideline on similar biological medicinal products containing monoclonal antibodies\u2014non-clinical and clinical issues. 2012. [cited 2020] Avaliable from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf."},{"key":"e_1_3_8_21_1","unstructured":"FDA. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. [cited 2020] Avaliable from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf."},{"key":"e_1_3_8_22_1","unstructured":"WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs). [cited 2020] Avaliable from: https:\/\/www.who.int\/biologicals\/publications\/trs\/areas\/biological_therapeutics\/TRS_977_Annex_2.pdf."},{"key":"e_1_3_8_23_1","unstructured":"FDA. Guidance for industry immunogenicity assessment for therapeutic protein products. [EB\/OL]. 2014. [cited 2020]. Available from: https:\/\/www.fda.gov\/media\/85017\/download."},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3416-4"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3695-4"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774506069153"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2701-3"},{"key":"e_1_3_8_29_1","unstructured":"FDA. Guidance for industry-clinical pharmacology data to support a demonstration of biosimilarity to a reference product[EB\/OL]. [cited 2020]. Available from: https:\/\/www.fda.gov\/media\/88622\/download."},{"key":"e_1_3_8_30_1","unstructured":"EMA. Guideline on similar biological medicinal products containing monoclonal antibodiesnon-clinical and clinical issues. EMA\/CHMP\/BMWP\/403543\/2010.[EB\/OL]. [cited 2020]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinalproducts-containing-monoclonal-antibodies-non-clinical_en.pdf."},{"key":"e_1_3_8_31_1","unstructured":"WHO. Guidelines on evaluation of monoclonal antibodies as similar biotherapeutic products (SBPs). No. 1004 2017.[EB\/OL]. [cited 2020]. Available from: https:\/\/www.who.int\/biologicals\/biotherapeutics\/WHO_TRS_1004_web_Annex_2.pdf?ua=1."},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00340-x"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1347635"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3001-2"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-04014-x"},{"key":"e_1_3_8_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00905"},{"key":"e_1_3_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00352-7"},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13691"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP203349"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14055"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00377-y"},{"key":"e_1_3_8_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1770226"},{"key":"e_1_3_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0664-8"},{"key":"e_1_3_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.11.015"},{"key":"e_1_3_8_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597600-000000000-00000"},{"key":"e_1_3_8_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft008"},{"key":"e_1_3_8_47_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9251-3"},{"key":"e_1_3_8_48_1","unstructured":"EMA. Guideline on Immunogenicity assessment of therapeutic proteins.[EB\/OL]. 2017. [cited 2020]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf."}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2021.1954157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:14:37Z","timestamp":1721625277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2021.1954157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1080\/14712598.2021.1954157"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2021.1954157","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"type":"print","value":"1471-2598"},{"type":"electronic","value":"1744-7682"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}